Rechallenge With 177Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer: Lessons From a Multicase Experience.

Authors

Faeze Rabani, Nikoo Rezaei, Amin Tanha Saber, Emran Askari, Atena Aghaee, Kamran Aryana

Published in

Clinical nuclear medicine. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

We report 4 patients with metastatic hormone-sensitive (mHSPC) or castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617 radioligand therapy (RLT), including rechallenge after disease progression. Initial RLT induced significant PSA declines, pain relief, and radiographic responses. Upon biochemical or clinical progression, rechallenge with additional 177Lu-PSMA cycles achieved renewed PSA reductions, sustained symptomatic improvement, and favorable safety, with no grade III-IV hematologic or renal toxicities. These cases illustrate the dynamic application of 177Lu-PSMA across disease stages and suggest that prior exposure does not preclude subsequent retreatment, supporting the feasibility and efficacy of RLT rechallenge in both mCRPC and mHSPC settings.

PMID:
42544985
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.